Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | NOS2 | P35228 | 3/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4864165 | 1.00 | ALDH1A1 (0.40) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL28066099 | 0.97 | ALDH1A1 (0.42) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL7009533 | 0.97 | ALDH1A1 (0.42) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL1865812 | 0.97 | ALDH1A1 (0.42) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL6889659 | 0.97 | ALDH1A1 (0.42) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL6889662 | 0.97 | ALDH1A1 (0.42) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL16512839 | 0.92 | ALDH1A1 (0.35) | ALDH1A1MAPTTRIM24TRIM33 | |
| SCHEMBL11593525 | 0.92 | ALDH1A1 (0.35) | ALDH1A1MAPTTRIM24TRIM33 | |
| SCHEMBL4866556 | 0.90 | ALDH1A1 (0.41) | ALDH1A1MAPTTRIM24TRIM33KMT2A | |
| SCHEMBL11330899 | 0.90 | TRIM24 (0.48) | ALDH1A1MAPTTRIM24TRIM33KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874301-A4 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080125310-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-29 | — | — | US | disclosed |
| US-7323604-B2 | Hydride reduction of α,β-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1874301-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113150-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-07-20 | — | — | US | disclosed |
| US-4251398-A | FOR ENHANCING OTHER ODORS, SCENTING TOILETRIES | FIRMENICH SA (CH) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054423-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | FFAR1, HCAR1, GPR119 | ALDH1A1 949/4885MAPT 2698/4885TRIM24 4294/4885 |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | ECH1, CBR1, DHCR24 | ALDH1A1 14/4885MAPT 2535/4885TRIM24 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.